Carbapenem resistance in clinical isolates of Pseudomonas aeruginosa

Journal of Chemotherapy

Volumn 19, Issue 4, 2007, Pages 376-381

  Walsh, Fiona ^a,b   Amyes, S G B ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Efflux; Meropenem; Pseudomonas aeruginosa

Indexed keywords

BACTERIAL PROTEIN; CARBAPENEM; GLUTAMINE; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PROTEIN MEXR; PROTEIN MEXT; PROTEIN OPRD; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PSEUDOMONAS AERUGINOSA; STOP CODON; UPREGULATION;

EID: 34547746867     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.4.376     Document Type: Article

References (28)

1. Lynch III JP. Hospital-acquired pneumonia. Risk factors, microbiology, and treatment. Chest 2001;119:Suppl: S373-84.
2. Köhler T, Epp SE, Curty LK, Pechere JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacterid 1999;181:6300-05.
3. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247-50.
4. Livermore DM. Interplay of impermeability and chromosomal b-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36:2046-48.
5. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306-25.
6. Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986;154:289-294.
7. Dib C, Trias J, Jarlier V. Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1995;14:979-986.
8. Wolter DJ, Smith-Moland E, Goering RV,Hanson ND, Lister PD. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagn Microbiol Infect Dis. 2004;50:43-50.
9. Pournaras S, Maniati M, Spanakis N, Ikonomidis A, Tassios PT, Tsakris A, et al. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase- producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity. J Antimicrob Chemother. 2005;56:761-764.
10. Walsh F, Bracher S, Turner P, Amyes SG. Epidemiological analysis of carbapenem-sensitive and -resistant Pseudomonas aeruginosa. J Hosp Infect 2005;60:240-244.
11. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001;48:Suppl: S1 5-16.
12. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001;48:Suppl: S1 17-28.
13. Valdezate S, Vindel A, Echeita A, Baquero F, Canto R. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrob Agents Chemother. 2002;46:665-71.
14. Renau TE, Léger R, Flamme EM, Sangalang J, She MW, Yen R, et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem 1999;42:4928-4931.
15. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000;38:1290-92.
16. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol 1996;34:2909-13.
17. Poole K, Tetro K, Zhao Q Neshat S, Heinrichs DE, Bianco N. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother 1996;40:2021-28.
18. Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999;43:424-27.
19. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-67.
20. Masuda N, Sakagawa, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:645-49.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
22. Conejo MC, Garcia I, Martinez-Martinez L Picabea L, Pascual A. Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2003;47:2313-2315.
23. Pai H., Kim J, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 2001;45:480-484.
24. Ziha-Zarifi I.Llanes C, Köhler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob. Agents Chemother 1999 43;2:287-91.
25. Ochs MM, McCusker MP, Bains M, Hancock RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 1999;43:1085-90.
26. Maseda H, Saito K, Nakajima A, Nakae T. Variation of the mexT gene, a regulator of the MexEF-OprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. FEMS Microbiol Lett 2000;192:107-12.
27. Hosaka M, Gotoh N, Nishino T. Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ. Antimicrob Agents Chemother 1995;39:1731-35.
28. El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005;113:187-96.